Search

Your search keyword '"Flaris, Alexandros"' showing total 27 results
Start Over Author "Flaris, Alexandros"
27 results on '"Flaris, Alexandros"'

14. Gastric Pneumatosis With Portal Venous Gas Can Be Treated Non-operatively: a Retrospective Multi-institutional Study

Author

Epin, Antoine, primary, Passot, Guillaume, additional, Christou, Niki, additional, Monneuse, Olivier, additional, Mabrut, Jean-Yves, additional, Ferrero, Pierre-Alexandre, additional, Caudron, Sebastien, additional, Pezet, Denis, additional, Magnin, Benoit, additional, Grange, Rémi, additional, Lambert, Céline, additional, Williet, Nicolas, additional, Flaris, Alexandros N., additional, and Roy, Bertrand Le, additional

Published
2021
Full Text
View/download PDF

25. Étude des modifications mitochondriales lors du choc hémorragique (traité avec du remplissage) chez le rat, avec la coloration « Oxydase du Cytochrome C » au microscope optique

Author

Flaris, Alexandros N., Passaret, Audrey, Vogt, Catherine, Prat, Nicolas, Reynard, Floran, Konstantinidou, Aphrodite, and Voiglio, Eric J.

Abstract

Le choc hémorragique est une des causes principales de décès chez les traumatisés. Lors du choc, les mitochondries gonflent et leur activité enzymatique diminue. Ces changements ont déjà été étudiés avec le microscope électronique, mais rarement avec le microscope optique. Le but de cette étude était d’étudier les changements structurels et fonctionnels de l’ensemble de mitochondries chez le rat, lors du choc hémorragique traité, avec la coloration « Oxydase du Cytochrome C » (COX) au microscope optique.

Published
2015
Full Text
View/download PDF

26. Burden of Comorbidities in Patients with OSAS and COPD-OSAS Overlap Syndrome

Author

Alexandros N. Flaris, Athanasios Voulgaris, Sophia E. Schiza, Paschalis Steiropoulos, Paschalis Ntolios, Kostas Archontogeorgis, Athanasia Pataka, Maria R. Bonsignore, Voulgaris, Athanasio, Archontogeorgis, Kosta, Pataka, Athanasia, Flaris, Alexandros N., Ntolios, Paschali, Bonsignore, Maria R., Schiza, Sophia, and Steiropoulos, Paschalis

Subjects
comorbiditie, medicine.medical_specialty, Medicine (General), obstructive sleep apnea syndrome, Comorbidity, Settore MED/10 - Malattie Dell'Apparato Respiratorio, overlap syndrome, comorbidities, Article, chronic obstructive pulmonary disease, FEV1/FVC ratio, Pulmonary Disease, Chronic Obstructive, R5-920, cardiovascular disease, Internal medicine, medicine, Humans, Retrospective Studies, COPD, Sleep Apnea, Obstructive, business.industry, Overlap syndrome, General Medicine, medicine.disease, nervous system diseases, Respiratory Function Tests, respiratory tract diseases, Obstructive sleep apnea, Apnea–hypopnea index, Cohort, business, Dyslipidemia
Abstract

Background and Objectives: Obstructive sleep apnea syndrome (OSAS) and chronic obstructive pulmonary disease (COPD) are usually associated with multi-morbidity. The aim of this study was to retrospectively investigate the prevalence of comorbidities in a cohort of patients with OSAS and COPD-OSAS overlap syndrome (OS) patients and to explore differences between these two groups. Materials and Methods: Included were consecutive OS patients and OSAS patients who had been referred to our sleep laboratory, and were matched in terms of sex, age, BMI, and smoking history. Presence of comorbidities was recorded based on their medical history and after clinical and laboratory examination. Results: The two groups, OS patients (n = 163, AHI &gt, 5/h and FEV1/FVC &lt, 0.7) and OSAS patients (n = 163, AHI &gt, 5/h, and FEV1/FVC &gt, 0.7), did not differ in terms of apnea hypopnea index (p = 0.346), and oxygen desaturation index (p = 0.668). Compared to OSAS patients, OS patients had lower average SpO2 (p = 0.008) and higher sleep time with oxygen saturation &lt, 90% (p = 0.002) during sleep, and lower PaO2 (p &lt, 0.001) and higher PaCO2 (p = 0.04) in wakefulness. Arterial hypertension was the most prevalent comorbidity for both OS and OSAS, followed by dyslipidemia, cardiovascular disease (CVD) and diabetes. OS was characterized by a higher prevalence of total comorbidities (median (IQR):2 (1–3) vs. 2 (1–2), p = 0.033), which was due to the higher prevalence of CVD (p = 0.016) than OSAS. No differences were observed in other comorbidities. Conclusions: In OS patients, nocturnal hypoxia and impaired gas exchange in wakefulness are more overt, while a higher burden of CVD is observed among them in comparison to sex-, age- and BMI-matched OSAS patients.

Published
2021

27. Is biochemical screening enough to guide calcium-sensing receptor gene mutational analysis when diagnosing familial hypocalciuric hypercalcemia? A retrospective study.

Author

Flaris AN, Julsrud TO, Vierkant RA, Foster TR, Dy BM, McKenzie TJ, Wermers RA, and Lyden ML

Abstract

Background: The American Association of Endocrine Surgeons suggests screening for familial hypocalciuric hypercalcemia for 24-hour urine calcium <100 mg and for calcium to creatinine clearance ratio <1%. We explored the biochemical and clinical profiles of genetically tested patients to determine the usefulness of these recommendations., Methods: This was a retrospective review of patients who underwent analysis of the calcium-sensing receptor gene., Results: In total, 401 patients were identified between 2005 and 2024; 332 (83%) were negative for a mutation, 44 (11%) were positive, and 25 (6%) had variants of unknown significance. Median serum calcium was lower in patients who were negative (negative 10.1 mg/dL, variants of unknown significance 10.6 mg/dL, positive 10.9 mg/dL). Median urine calcium was lower in patients who were positive (negative 110 mg, variants of unknown significance 149 mg, positive 82 mg). Median parathyroid hormone levels were comparable between groups (negative 65 pg/mL, variants of unknown significance 58 pg/mL, positive 60 pg/mL). Eight of 21 (38%) patients who tested positive had urine calcium >100 mg and 5 of 21 (24%) had urine calcium >200 mg. Eight of 35 (23%) patients who were positive had a calcium to creatinine clearance ratio >1%. Urine calcium and calcium to creatinine clearance ratio receiver operating characteristic curves showed poor performance in identifying patients with familial hypocalciuric hypercalcemia (area under the curve [95% confidence interval]): 0.55 [0.45-0.65] and 0.63 [0.57-0.7], respectively. For positive patients with imaging, sestamibi was inconclusive or nonlocalizing for 13 of 23 and showed multiglandular disease for localizing scans in 7 of 10. Ultrasound was nonlocalizing or equivocal for 11 of 13. In total, 212 of 401 patients (53%) underwent surgery; 100 of 212 were tested preoperatively (0/100 positive, 5/100 variants of unknown significance) and 112 of 212 patients were tested postoperatively (15/112 positive, 10/112 variants of unknown significance)., Conclusion: Familial hypocalciuric hypercalcemia demonstrates non-negligible biochemical overlap with primary hyperparathyroidism, with many patients having a urine calcium value greater than the American Association of Endocrine Surgeons suggested threshold for considering genetic evaluation. More frequent genetic testing beyond urine measurements may help identify more patients with familial hypocalciuric hypercalcemia., Competing Interests: Conflict of Interest/Disclosure The authors have no related conflicts of interest to declare., (Copyright © 2024 Elsevier Inc. All rights reserved.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results